ArticleBiotechnology letters2025
An effective strategy for soluble bovine enterokinase expression in Escherichia coli.
Article in Biotechnology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Designing an optimized strategy for extracellular expression of recombinant human TNF-α inFrontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bovine enterokinase light chain (bEkL) is a serine protease, widely used for the specific cleavage of affinity tags from various recombinant proteins. However, getting soluble expression in Escherichia coli is a challenging task given the presence of multiple cysteines and four disulfide bonds. Strategies that have only been partially successful involve mutating the gene or covalent attachment of solubility tags. We demonstrate a simpler and more efficient production method that combines different strategies like co-expressing the GroES-GroEL chaperone in E. coli SHuffle cells, lowering temperatures to 18 °C post-induction, and ensuring the sufficient accumulation of GroES-GroEL in the cytoplasm before inducing the bEkL gene. A trade-off exists between producing too little GroES-GroEL and promoting inclusion body formation (of bEkL) or expressing too much GroES-GroEL thereby reducing bEkL yields. This optimum level was determined by varying the time difference between the two inductions, and the best results obtained when the co-expressed pGro7 plasmid was induced 2 h before bEkL induction, thus avoiding inclusion body formation. Interestingly, when we delayed the induction of GroES-GroEL to an OD
Indexed as
Identifiers
41042389What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.